Stocks and Investing
Stocks and Investing
Wed, July 13, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Benjamin Burnett Downgraded (ATRA) to Hold and Decreased Target to $125 on, Jul 13th, 2022
Benjamin Burnett of Stifel, Downgraded "Atara Biotherapeutics, Inc." (ATRA) to Hold and Decreased Target from $400 to $125 on, Jul 13th, 2022.
Benjamin has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 1 agrees with Benjamin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yigal Nochomovitz of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $200 on, Tuesday, May 10th, 2022
These are the ratings of the 2 analyists that currently disagree with Benjamin
- Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $100 on, Tuesday, May 24th, 2022
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $725 on, Monday, May 23rd, 2022
Contributing Sources